摘要
目的:筛选升麻药材中治疗乙型病毒性肝炎的药用活性部位。方法:采用树脂分离技术,制备升麻总酚酸、总皂苷部位,并以拉米夫定为阳性药,选择HBV转基因小鼠作为受试动物,以小鼠血清中HBsAg及HBeAg为指标;以HepG2-2.2.15细胞株为模型,检测细胞内核心颗粒HBV DNA的变化,考察升麻水提液、总酚酸、总皂苷、升麻苷及阿魏酸5个组分对HBsAg及HBeAg的影响。结果:5个组别对小鼠血清中HBsAg及HBeAg均有一定的降低作用,且总酚酸显著降低HBsAg及HBeAg,与对照组有显著性差异(P<0.01),且阿魏酸是其中的有效成分;总皂苷可以降低HBsAg,与对照组有较显著性差异(P<0.05),但是升麻苷对HBsAg及HBeAg的作用均无显著性差异;升麻总酚酸能明显降低HepG2-2.2.15细胞胞浆核心颗粒HBV DNA水平(P<0.01)。结论:升麻中的总酚酸部位是其治疗乙型病毒性肝炎的药用活性部位,本研究为治疗乙型病毒性肝炎的药物开发提供了数据参考。
Objective： To study the potent active components of Cimicifugae Rhizoma for treating hepatitis B virus （HBV）. Method： The total phenolic acid and saponins of Cimicifugae Rhizoma were separated by nmcroporous resin, HBV DNA, HBsAg and HBeAg were observed to analyze the anti-hepatitis B virus effect of prim-o-glucosylcimifugin, ferulic acid, Cimicifugae Rhizoma aqueous extract solution, Cimicifugae Rhizoma phenolic acid and Cimicifugae Rhizoma saponins. Result： The five groups significantly reduced the concentration of HBsAg and HBeAg. Compared with the blank control group, the total phenolic acid can decrease the HBsAg and HBeAg （P 〈0.01 ） and the ferulic acid was the potential active component, Cimicifugae Rhizoma saponins can reduce the HBsAg （P 〈 0.05） but prim-o-glucosylcimifugin have no obvious anti-hepatitis B virus effect. The total phenolic acid of Cimicifugae Rhizoma can remarkably decrease the level of viral core associated-HBV DNA in the cytoplasm. Conclusion： The total phenolic acid of Cimicifugae Rhizoma is the active part to anti-hepatitis B virus effect, and the results provide the basis of screening new drugs for treatment hepatitis B virus.
出处
《中国实验方剂学杂志》
CAS
北大核心
2013年第21期231-235,共5页
Chinese Journal of Experimental Traditional Medical Formulae
基金
南京中医药大学中药学一级学科开放课题(2011ZYX3-008)
康缘中医药科技创新基金(HZ1006KY)
关键词
升麻
乙型病毒性肝炎
酚酸
皂苷
升麻苷
阿魏酸
Cimicifugae Rhizoma
hepatitis B virus
phenolic acid
saponin
prim-o-glucosylcimifugin
ferulic acid
